The Effect of SAAE on Ventricular Remodeling in PA Patients

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital of Nanchang University
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• (1) Age 18-60 years old, regardless of gender;

• (2) Blood pressure conditions meet one of the following: 1) Office blood pressure ≥ 140/90mmHg; 2) Ambulatory blood pressure monitoring whole day blood pressure > 130/80 mmHg or daytime blood pressure > 135/85 mmHg;

• (3) After strict drug elution, it met the diagnostic criteria of primary aldosteronism, and bilateral primary aldosteronism was confirmed by adrenal venous sampling;

• (4) No surgical intent or contraindication to surgery and willing to undergo pharmacological treatment or percutaneous superselective adrenal artery embolization;

• (5) The patient or his/her legal representative shall sign the written informed consent approved by the ethics committee before the screening.

Exclusion Criteria:

• (1) Primary hypertension or secondary hypertension with other causes;

• (2) A woman who is pregnant or lactating, or has a birth plan for the next year;

• (3) There are serious organic diseases, especially liver and kidney dysfunction(eGFR<45 mL/min/1.73 m2);

• (4) Severe allergy to contrast medium;

• (5) Other serious organic diseases, life expectancy < 12 months;

• (6) Adrenal CT showed adenoma.;

• (7) Patients are enrolled or want to participate in other clinical studies. During the enrollment study, the results of this study will be affected.